DNL201

DRUG2 trials

Sponsors

Denali Therapeutics Inc.

Conditions

Healthy VolunteersParkinson Disease

Phase 1

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

CompletedNCT03710707

Denali Therapeutics Inc.Parkinson Disease

Start: 2018-12-04End: 2019-12-06Updated: 2020-01-13

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

CompletedNCT04551534

Denali Therapeutics Inc.Healthy Volunteers

Start: 2017-06-01End: 2018-08-08Updated: 2020-09-16

Related Papers

LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.

2025-08-062 citations

Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents.

2025-07-18

Genetic Testing for <scp><i>GBA</i></scp> and <scp><i>LRRK2</i></scp> Mutations: Is it Time for Routine Use?

Movement Disorders Clinical Practice2022-11-112 citations

LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort

Frontiers in Neurology2021-08-098 citations